{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 459444391
| IUPAC_name               = 3-fluoro-6-(4-methylpiperazin-1-yl)-11''H''-dibenzo[b,e]azepine
| image                    = Fluperlapine.svg
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number               = 67121-76-0
| ATC_prefix               = none
| ATC_suffix               = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = EWG253M961
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 63756
| PubChem                  = 49381
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID             = 44882
| C = 19 | H = 20 | F = 1 | N = 3
| molecular_weight         = 309.381 g/mol
| smiles                   = Fc4ccc3c(/N=C(/N1CCN(C)CC1)c2ccccc2C3)c4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI                 = 1S/C19H20FN3/c1-22-8-10-23(11-9-22)19-17-5-3-2-4-14(17)12-15-6-7-16(20)13-18(15)21-19/h2-7,13H,8-12H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey              = OBWGMKKHCLHVIE-UHFFFAOYSA-N
| bioavailability          = 
| protein_bound            = 
| metabolism               = 
| elimination_half-life    = 
| excretion                = 
| pregnancy_category       = 
| legal_status             = 
| routes_of_administration = 
}}

'''Fluperlapine''' ('''NB 106-689'''), also known as '''fluoroperlapine''', is a [[morphanthridine]] (11''H''-dibenzo[b,e]azepine
) [[atypical antipsychotic]] with additional [[antidepressant]] and [[sedative]] effects. It was first [[chemical synthesis|synthesized]] in 1979, and then subsequently studied in animals and humans in 1984 and beyond,<ref name=Ganellin>
{{cite book 
| last1      = Ganellin  | first1 = C. R. 
| last2      = Triggle   | first2 = D. J. 
| last3      = Macdonald | first3 = F.
| title      = Dictionary of pharmacological agents 
| url        = https://books.google.com/books?id=DeX7jgInYFMC&pg=PA916 
| accessdate = 15 September 2011 
| year       = 1997 
| publisher  = [[CRC Press]] 
| isbn       = 978-0-412-46630-4 
| page       = 916
}}</ref> but despite demonstrating efficacy in the treatment of a variety of [[medical condition]]s including [[schizophrenia]],<ref name="pmid6145428">
{{Cite journal 
| last1 = Fischer-Cornelssen | first1 = K. A. 
| title = Fluperlapine in 104 schizophrenic patients. Open multicenter trial 
| journal = Arzneimittel-Forschung 
| volume = 34 
| issue = 1A 
| pages = 125–130 
| year = 1984 
| pmid = 6145428
}}</ref><ref name="pmid6148712">
{{Cite journal 
| doi = 10.1159/000118064 
| last1 = Woggon | first1 = B. 
| last2 = Angst | first2 = J. 
| last3 = Bartels | first3 = M. 
| last4 = Heinrich | first4 = K. 
| last5 = Hippius | first5 = H. 
| last6 = Koukkou | first6 = M. 
| last7 = Krebs | first7 = E. 
| last8 = Küfferle | first8 = B. 
| last9 = Müller-Oerlinghausen | first9 = B. 
| last10 = Pöldinger | first10 = W. 
| last11 = r&Uuml;Ther | first11 = E. 
| last12 = Schied | first12 = H. W. 
| title = Antipsychotic efficacy of fluperlapine. An open multicenter trial 
| journal = Neuropsychobiology 
| volume = 11 
| issue = 2 
| pages = 116–120 
| year = 1984 
| pmid = 6148712
}}</ref><ref name="pmid6728910">
{{Cite journal 
| last1 = Dieterle | first1 = D. 
| last2 = Eben | first2 = E. 
| last3 = Einhäupl | first3 = K. 
| last4 = Hippius | first4 = H. 
| last5 = Klein | first5 = H. 
| last6 = Rüther | first6 = E. 
| last7 = Schmauß | first7 = M. 
| doi = 10.1055/s-2007-1017408 
| title = The Effect of Fluperlapine in Acute Psychotic Patients 
| journal = Pharmacopsychiatry 
| volume = 17 
| issue = 2 
| pages = 57–60 
| year = 2008 
| pmid = 6728910 
| pmc = 
}}</ref><ref name="pmid6145427">
{{Cite journal 
| last1 = Woggon | first1 = B. 
| last2 = Heinrich | first2 = K. 
| last3 = Küfferle | first3 = B. 
| last4 = Müller-Oerlinghausen | first4 = B. 
| last5 = Pöldinger | first5 = W. 
| last6 = Rüther | first6 = E. 
| last7 = Schied | first7 = H. W. 
| title = Results of a multicenter AMDP study with fluperlapine in schizophrenic patients 
| journal = Arzneimittel-Forschung 
| volume = 34 
| issue = 1A 
| pages = 122–124 
| year = 1984 
| pmid = 6145427
}}</ref> [[psychosis]] associated with [[Parkinson's disease]],<ref name="pmid2864254">{{Cite journal 
| last1 = Scholz | first1 = E. 
| last2 = Dichgans | first2 = J. 
| title = Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine 
| journal = European Archives of Psychiatry and Neurological Sciences 
| volume = 235 
| issue = 1 
| pages = 60–64 
| year = 1985 
| pmid = 2864254
 | doi=10.1007/bf00380972
}}</ref> [[major depression|depressive symptoms]], and [[dystonia]],<ref name="pmid2860654">
{{Cite journal 
| last1   = Pakkenberg | first1 = H. 
| last2   = Pedersen   | first2 = B. 
| title   = Medical treatment of dystonia 
| journal = Psychopharmacology. Supplementum 
| volume  = 2 
| issn    = 0179-8456 
| oclc    = 10642795
| pages   = 111–117 
| year    = 1985 
| pmid    = 2860654
 | doi=10.1007/978-3-642-70140-5_14
| series = Psychopharmacology Supplementum 
| isbn = 978-3-642-70142-9 
}}</ref> it was never marketed.<ref name=Ganellin/>
This was perhaps due to its capacity for producing potentially life-threatening [[agranulocytosis]], similarly to clozapine,<ref name="pmid10681368">{{Cite journal 
| last1 = Lai | first1 = W. G. 
| last2 = Gardner | first2 = I. 
| last3 = Zahid | first3 = N. 
| last4 = Uetrecht | first4 = J. P. 
| title = Bioactivation and covalent binding of hydroxyfluperlapine in human neutrophils: Implications for fluperlapine-induced agranulocytosis 
| journal = Drug metabolism and disposition: the biological fate of chemicals 
| volume = 28 
| issue = 3 
| pages = 255–263 
| year = 2000 
| pmid = 10681368
}}</ref> which it closely resembles both [[chemistry|structurally]] and [[pharmacology|pharmacologically]].

==Pharmacology==
'''Binding profile'''<ref>{{cite web|title=PDSP K<sub>i</sub> Database |work=Psychoactive Drug Screening Program (PDSP) |author1=Roth, BL |author2=Driscol, J |url=http://pdsp.med.unc.edu/pdsp.php |publisher=University of North Carolina at Chapel Hill and the United States National Institute of Mental Health |accessdate=3 December 2013 |date=12 January 2011 |deadurl=yes |archiveurl=https://web.archive.org/web/20131108013656/http://pdsp.med.unc.edu/pdsp.php |archivedate=8 November 2013 |df= }}</ref>
{| class = wikitable
! Receptor !! K<sub>i</sub> (nM)
|-
| 5-HT<sub>2A</sub> || 7.9
|-
| 5-HT<sub>2C</sub> || 18.2
|-
| 5-HT<sub>6</sub> || 29
|-
| 5-HT<sub>7</sub> || 4.6
|-
| M<sub>1</sub> || 8.8
|-
| M<sub>2</sub> || 71
|-
| M<sub>3</sub> || 41
|-
| M<sub>4</sub> || 14
|-
| M<sub>5</sub> || 17
|-
| D<sub>1</sub> || 85
|-
| D<sub>2</sub> || 316.2
|-
| D<sub>3</sub> || 254.7
|-
| D<sub>4</sub> || 21
|}

== See also ==
* [[Clozapine]]
* [[Perlapine]]

== References ==
{{Reflist}}

{{Antipsychotics}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Dopamine receptor modulators}}
{{Histamine receptor modulators}}
{{Muscarinic acetylcholine receptor modulators}}
{{Serotonin receptor modulators}}
}}
{{Tricyclics}}

[[Category:Antipsychotics]]
[[Category:Dibenzazepines]]
[[Category:Muscarinic antagonists]]
[[Category:Piperazines]]
[[Category:Sedatives]]
[[Category:Tricyclic antidepressants]]